![Bowers_46](https://www.hivplusmag.com/media-library/bowers-46.jpg?id=32675464&width=1200&height=1640)
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
In my latest article I wrote about the three newest drugs we have been blessed with: Intelence, Isentress, and Selzentry. All were approved by the Food and Drug Administration based on 24-week data from clinical trials, which means that enough patients had their viralload reduced to less than 50 after six months that the FDA was willing to approve the drug while more long-term results were collected. So it was reassuring to hear at this year's Conference on Retroviruses and Opportunistic Infections that the 48-week data confirmed their effectiveness. Selzentry and Isentress were approved in the second half of 2007, and each was the first drug in a totally new class of antiretrovirals. Intelence, approved in January, is a nonnucleoside reverse transcriptase inhibitor, like Sustiva and Viramune, but because it has resistance mutations different from the other nonnukes, it has the potential to have an impact on treatment options that are nearly the same as having another new drug class available. With Sustiva and Viramune, one single mutation at location K103N causes complete loss of anti-HIV activity by both drugs. Needless to say, K103N is now a common mutation. Intelence, on the other hand, is not affected by K103N. In fact, of the 12 nonnuke-resistant mutations defined by the International AIDS Society, it takes three or more mutations to reduce the effectiveness of this drug. In essence, it can resurrect the nonnucleoside class. As with Selzentry and Isentress, Intelence was approved based on a trial of three-class-resistant patients who were given an optimized salvage regimen with either Intelence or a placebo. At 48 weeks 61% of the patients on Intelence had undetectable viral loads compared to 40% who were given a placebo. Interestingly, in patients whose salvage regimen contained no other active drug, Intelence by itself got 45% of them to undetectability. Intelence is dosed as two tablets to be taken twice a day with food. A rash occurred in 17% of patients, mostly between weeks two and four, but only 2% of patients stopped the drug due to the rash. Nausea occurred in 14% of patients versus 11% of patients who were on a placebo (remember these were multidrug salvage regimens that they were being given). The one issue with this drug is its somewhat complicated metabolism pathways, which limit its combining options. While Intelence can be combined with any nucleoside reverse transcriptase inhibitor, the only protease inhibitors that it can be used with are Invirase or Prezista (each boosted) or with Kaletra. And it cannot be combined with any of the other nonnucleosides. Despite theses restrictions, we can extend a warm welcome to this newest kid on the block.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
Plus: Featured Video
Latest Stories
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Advocacy in action with AIDSWatch
May 09 2024 12:30 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
The Talk: Finding balance with HIV
May 06 2024 10:51 AM
Justice Dept plans to reschedule marijuana as a lower-risk drug
May 03 2024 2:40 PM
The Talk: Starting your journey with HIV
May 03 2024 2:00 PM
Why is a mother’s mental health so important? A doctor explains
May 01 2024 1:38 PM
Walmart to close all of its health care clinics
April 30 2024 12:30 PM
Vampire facial spa infected several women with HIV
April 29 2024 7:26 PM